Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study.

被引：0
|
作者：
Berg, SL
Blaney, SM
Bernstein, M
Kurtzberg, J
Devidas, M
Lampkin, T
Murgo, AJ
Harris, MB
机构：
[1] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[2] Hop St Justine, Montreal, PQ H3T 1C5, Canada
[3] Duke Univ, Med Ctr, Durham, NC 27706 USA
[4] Childrens Oncol Grp, Gainesville, FL USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA
[7] Hackensack Univ, Tomorrow Childrens Inst, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
792
引用
收藏
页码：226A / 226A
页数：1
相关论文
共 50 条
  • [41] Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study
    Dupuis, Jehan
    Tsukasaki, Kunihiro
    Bachy, Emmanuel
    Morschhauser, Franck
    Cartron, Guillaume
    Fukuhara, Noriko
    Daguindau, Nicolas
    Casasnovas, Rene-Olivier
    Snauwaert, Sylvia
    Gressin, Remy
    Fox, Christopher P.
    d'Amore, Francesco Annibale
    Staber, Philipp B.
    Gkasiamis, Argyrios
    Nishio, Mitsufumi
    Fornecker, Luc-Matthieu
    Delfau, Marie-Helene
    Sako, Nouhoum
    Mule, Sebastien
    De Leval, Laurence
    Gaulard, Philippe
    Lemonnier, Francois
    BLOOD, 2022, 140 : 2310 - 2312
  • [42] A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Strati, Paolo
    Chihara, Dai
    Oki, Yasuhiro
    Fayad, Luis E.
    Fowler, Nathan
    Nastoupil, Loretta
    Romaguera, Jorge E.
    Samaniego, Felipe
    Garg, Naveen
    Feng, Lei
    Wesson, Emily T.
    Ruben, Charnelle E.
    Stafford, Mildred D.
    Nieto, Yago
    Khouri, Issa F.
    Hosing, Chitra
    Horowitz, Sandra B.
    T-Kamble, Rammurti
    Fanale, Michelle A.
    HAEMATOLOGICA, 2018, 103 (09) : E416 - E418
  • [43] Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
    Negoro, Eiju
    Yamauchi, Takahiro
    Fukuhara, Noriko
    Yamamoto, Kazuhito
    Uchida, Toshiki
    Izutsu, Koji
    Maruyama, Dai
    Terui, Yasuhito
    Nakajima, Hideaki
    Ando, Kiyoshi
    Suehiro, Youko
    Choi, Ilseung
    Kanemura, Nobuhiro
    Nakamura, Nobuhiko
    Yamamoto, Go
    Maeda, Yoshinobu
    Shibayama, Hirohiko
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    Tien, Hwei-Fang
    Kwong, Yok-Lam
    Kim, Won-Seog
    Tobinai, Kensei
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (02) : 108 - 120
  • [44] E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study
    Ohmachi, Ken
    Ando, Kiyoshi
    Ogura, Michinori
    Uchida, Toshiki
    Tobinai, Kensei
    Maruyama, Dai
    Namiki, Masayuki
    Nakanishi, Tadashi
    CANCER SCIENCE, 2018, 109 (03): : 794 - 802
  • [45] Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory T-cell lymphoma.
    Zinzani, PL
    Tani, M
    Stefoni, V
    Alinari, L
    Marchi, E
    Fina, M
    Baccarani, M
    BLOOD, 2005, 106 (11) : 271B - 271B
  • [46] Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma
    Kawai, Hidetsugu
    Ando, Kiyoshi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Kiyohara, Eiji
    Terui, Yasuhito
    Fukuhara, Noriko
    Miyagaki, Tomomitsu
    Tokura, Yoshiki
    Sakata-Yanagimoto, Mamiko
    Igarashi, Tadahiko
    Kuroda, Junya
    Fujita, Jiro
    Uchida, Toshiki
    Ishikawa, Takayuki
    Yonekura, Kentaro
    Kato, Koji
    Nakanishi, Tadashi
    Nakai, Kenya
    Matsunaga, Risa
    Tobinai, Kensei
    CANCER SCIENCE, 2021, 112 (06) : 2426 - 2435
  • [47] Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma
    Duvic, M
    Ziari, S
    Olsen, EA
    Foss, FM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 615S - 615S
  • [48] Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
    Tang, Tiffany
    Martin, Peter
    Somasundaram, Nagavalli
    Lim, Cindy
    Tao, Miriam
    Poon, Eileen
    Yunon, Maica J. D.
    Toh, Shu Q.
    Yan, Sean X.
    Farid, Mohamad
    Chan, Jason Y.
    Lim, Soon T.
    HAEMATOLOGICA, 2021, 106 (12) : 3170 - 3175
  • [49] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
    Mehta-Shah, Neha
    Zinzani, Pier Luigi
    Jacobsen, Eric D.
    Zain, Jasmine
    Mead, Monica
    Casulo, Carla
    Gritti, Giuseppe
    Pinter-Brown, Lauren C.
    Izutsu, Koji
    Bentur, Ohad S.
    Sidransky, David
    Brammer, Jonathan E.
    Pro, Barbara
    Fox, Christopher P.
    Horwitz, Steven
    BLOOD, 2024, 144 : 3061 - 3062
  • [50] Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies
    Ogura, Michinori
    Tsukasaki, Kunihiro
    Nagai, Hirokazu
    Uchida, Toshiki
    Oyama, Takashi
    Suzuki, Tatsuya
    Taguchi, Jun
    Maruyama, Dai
    Hotta, Tomomitsu
    Tobinai, Kensei
    CANCER SCIENCE, 2012, 103 (07) : 1290 - 1295
12345